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Abstract
This work describes the coupling of the IR-MALDESI imaging source with the Q Exactive mass 
spectrometer. IR-MALDESI MSI was used to elucidate the spatial distribution of several HIV 
drugs in cervical tissues that had been incubated in either a low or high concentration. Serial 
sections to those analyzed by IR-MALDESI MSI were homogenized and analyzed by LC-MS/MS 
to quantify the amount of each drug present in the tissue. By comparing the two techniques, an 
agreement between the average intensities from the imaging experiment with the absolute 
quantities for each drug was observed. This correlation between these two techniques serves as a 
prerequisite to quantitative IR-MALDESI MSI. In addition, a targeted MS2 imaging experiment 
was also conducted to demonstrate the capabilities of the Q Exactive and to highlight the added 
selectivity that can be obtained with SRM or MRM imaging experiments.
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Introduction
Mass spectrometry imaging (MSI) is a method by which mass spectra are generated from 
discrete locations in a two dimensional array across a sample surface.[1] This combination 
of spatial information with the specificity and sensitivity of mass spectrometric detection 
make MSI a valuable tool in a variety of scientific fields.[2-9] One such example is the 
potential that MSI has demonstrated in the analysis of pharmaceuticals in tissue sections.
[10-12] Knowledge of the distribution of a drug, and in some cases its metabolites, within 
certain compartments or sub-compartments of a particular tissue can have numerous 
implications in the areas of drug pharmacokinetics and pharmacodynamics.[13-14] Whole-
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body autoradiography (WBA) is the predominant technique for the determination of drug 
distribution in tissue.[15] While WBA is a valuable quantitative technique, it shares an 
inherent flaw with all radiolabeled studies in that it only follows the distribution of the 
radiolabel and provides no information as to which form of the drug is being detected 
(parent or metabolite). Given that MSI is based on mass spectrometric detection, it is 
capable of distinguishing between the parent drug and its metabolites. Perhaps one of the 
most enticing attributes of MSI is its label-free nature that precludes the use of expensive 
radiolabels and allows for the simultaneous analysis of xenobiotics and endogenous 
compounds in a single global experimental approach. In some cases the additional 
knowledge gained from endogenous distributions can provide valuable insight on the impact 
of the drug on the local environment, implications for site-specific efficacy and toxicity, and 
can be used to identify certain histological features.[11, 16-18] MSI is befitting to drug 
discovery and development where the early understanding of preclinical drug distribution 
(and without requiring a radiolabel) can improve efficiency by narrowing the list of potential 
candidates.
Matrix-assisted laser desorption/ionization (MALDI) is perhaps the most common ionization 
technique that is currently used for MSI. Several characteristics of MALDI that make it a 
suitable match for MSI include its high sensitivity and small spot size which are 
prerequisites for high spatial resolution imaging.[19] There are, however, several issues 
regarding this technique including the requirement that the sample must be amenable to high 
vacuum as well as the extensive sample preparation that is involved prior to analysis.[20-21] 
Other ionization methods such as desorption electrospray (DESI), liquid extraction surface 
analysis (LESA), and matrix-assisted laser desorption electrospray ionization (MALDESI) 
have demonstrated promise for pharmaceutical tissue imaging with little to no prior sample 
preparation.[22-24]
MALDESI refers to any technique which involves resonant excitation of an endogenous or 
exogenous matrix to facilitate analyte desorption followed by post-ionization through ESI. 
The matrix described here refers to any molecule present in large excess that strongly 
absorbs the laser energy and leads to analyte ejection.[25] The first MALDESI publication 
was presented in 2006 by Muddiman as proof of principle using a UV laser (UV-
MALDESI) and a ubiquitin solution mixed with an organic acid matrix.[26] This resulted in 
the detection of multiply charged ubiquitin with a charge state distribution that was 
indistinguishable from that obtained by direct infusion ESI which affirmed electrospray 
post-ionization in the MALDESI mechanism. Muddiman, as well as several other research 
groups, have also explored the utility of other laser wavelengths for MALDESI in each case 
utilizing a matrix that strongly absorbed within the wavelength region of the laser emission.
[27-31] An exciting combination arose with the use of a Mid-IR laser (2.94 μm) with 
endogenous or exogenous water as the laser energy absorbing matrix (IR-MALDESI) which 
offers certain intrinsic benefits including the lack of matrix interference in the mass spectra 
and the natural occurrence of water in most biological samples. While the use of water as a 
matrix for IR laser desorption was not an entirely new concept,[32] ion yields for IR-
MALDI using ice were typically low.[33] Thus, post-ionization of the larger fraction of 
neutral molecules in the ablation plume using ESI could result in improved ion yields.[34] 
MSI using laser ablation electrospray ionization (LAESI), an analogue of IR-MALDESI, has 
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been presented using the endogenous water in the tissue as a laser energy absorbing matrix.
[35] However, we have found that depositing a uniform ice matrix over the sample surface 
provides improved reproducibility from pixel to pixel resulting in higher image quality.[24, 
36-37]
Due to the complex nature of biological tissue samples, MSI techniques rely heavily on the 
mass spectrometer to resolve species by m/z. Several groups have demonstrated the utility of 
coupling imaging sources with high resolving power mass spectrometers in order to resolve 
several unique species with the same nominal mass that often times have different spatial 
distributions.[11, 19, 36, 38-42] The primary benefits to imaging with Fourier transform 
(FT) mass spectrometers include not only the ability to increase the spectral peak capacity 
but also the ability to obtain accurate mass measurements that improve the confidence of ion 
identification. However, due to the relatively slow acquisition rates, FT imaging can be a 
time consuming process. The hybrid quadrupole orbitrap mass spectrometer (Q Exactive) 
has several unique features that make it highly amenable to MSI.[43] In addition to using the 
enhanced FT (eFT) to reduce the required transient times, the Q Exactive also allows for 
multiplexing capabilities to improve the overall duty cycle. Several groups demonstrated the 
application of the Q Exactive for MSI.[44-46]
The use of MSI to visually evaluate the distribution of drugs in tissue is of particular interest 
in the field of human immunodeficiency virus (HIV), an intracellular infection primarily of 
CD4+ T cells. In this disease, current limitations in assessing mucosal tissue antiretroviral 
drug distribution have slowed the progress of small molecule research in the prevention of 
HIV infection.[47] Moreover, an understanding of antiretroviral distribution in HIV tissue 
reservoirs, where low-level viral replication may still be occurring in the face of clinically 
effective antiretroviral therapy[48] will form the foundation of successful eradication 
strategies. Previous uses of MALDI in the HIV field have focused on the quantification of 
antiretrovirals in plasma,[49] and more recently MSI has been used to examine the 
disposition of a novel antiretroviral in brain tissue.[50] A reliable method of visually 
evaluating antiretroviral exposure in tissues relevant to HIV infection will greatly inform the 
development of novel therapies for HIV treatment, prevention, and cure.
Herein, we present on the coupling of the IR-MALDESI imaging source to the Q Exactive 
to determine the distribution of several commonly used antiretroviral drugs in incubated 
tissues. Imaging is performed as either a broadband acquisition to obtain a global 
perspective of the three drugs of interest with endogenous species or as a more selective 
targeted MS2 acquisition. In addition, tissue sections that are adjacent to those used for 
imaging were homogenized and analyzed by LC-MS/MS to quantify the total amounts of 
each drug present in the tissue. These values were then compared with the relative 
abundances from the imaging experiments to determine the quantitative capabilities of IR-
MALDESI MSI.
Barry et al. Page 3
























HPLC Grade methanol and water were purchased from Burdick and Jackson (Muskegon, 
MI) and formic acid was purchased from Sigma-Aldrich (St. Louis, MO). Emtricitabine, 
tenofovir and raltegravir were obtained from the NIH AIDS Reagent Program, directed by 
the Pathogenesis and Basic Research Branch, Basic Sciences Program, Division of AIDS 
(DAIDS), NIAID, NIH. All materials were used as purchased without further purification.
Samples
Cervical tissues were obtained from surgical waste via the University of North Carolina 
Tissue Procurement Facility through UNC IRB # 09-0921. Written informed consent was 
obtained from all patients. After harvest, tissues were placed immediately in culture media 
[Iscove's Modified Dulbecco's Media (Gibco, Grand Island, NY), 10% fetal bovine serum 
(Gibco), 240 units/mL nystatin (Sigma, St. Louis, MO), 100 units/mL penicillin-
streptomycin (Gibco), and MEM vitamin solution (Sigma)] and kept on ice until receipt into 
the laboratory. Once received into the lab, tissues were trimmed of fat and other connective 
tissue with sterile scissors and cut into approximately 1cm2 pieces. Pieces were placed into 
individual wells of a 24-well tissue culture plate with 1mL culture media containing low or 
high concentrations of the nucleoside reverse transcriptase inhibitors emtricitabine (FTC) 
and tenofovir (TFV) and the integrase strand transfer inhibitor raltegravir (RAL). Here, low 
concentrations were defined as 10 times the reported plasma Cmax value in humans for each 
drug: 18,000 ng/mL FTC, 3,800 ng/mL TFV, and 28,880 ng/mL RAL. High concentration 
was defined as 100,000 ng/mL for all three drugs. These concentrations were selected to 
mimic mucosal tissue concentrations seen clinically in Phase I studies.[51-52] The 
incubation concentration along with the exact monoisotopic mass for each drug is also 
presented in Table 1. All tissues were incubated for 24 hours at 37°C. After 24 hours, tissues 
were removed from drug and rinsed with fresh culture media before being frozen with dry 
ice vapor and stored at -80°C. Each tissue was sectioned at -20°C using a Leica CM1950 
cryomicroto me (Buffalo Grove, IL) into 10, 25, or 50 μm thick sections. The sections were 
then thaw-mounted onto glass microscope slides for imaging. Sections of each tissue were 
mounted adjacent to each other so that each glass slide contained a section of each tissue in 
the low and high concentrations at the same thickness. Sections that were serial cuts to those 
used for imaging were also collected for LC-MS quantitation.
IR-MALDESI Imaging
A more detailed description of the IR-MALDESI imaging source can be found elsewhere.
[36-37] In short, the tissue sample is placed on a liquid cooled thermoelectric stage that is 
cooled to -10°C while under nitrogen purge and is then exposed to the ambient environment 
in order to deposit a thin layer of ice over the surface of the tissue. Once the ice layer has 
been deposited, the enclosure around the source is purged with nitrogen to maintain a 
relative humidity of around 10 % which we have found to be the point where ice deposition 
and sublimation are close to equilibrium to preserve a consistent ice matrix layer throughout 
the course of the imaging experiment. A mid-IR laser tuned to 2.94 μm (IR-Opolette 2371, 
Opotek, Carlsbad, CA) is used to resonantly excite the ice matrix layer and facilitate the 
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desorption of neutral molecules from the tissue section. These neutrals then partition into the 
charged solvent droplets of an electrospray plume where ions are generated through an ESI-
like process. The geometry of the IR-MALDESI source has recently been optimized for 
tissue imaging.[37] For the imaging experiments, 50% (v/v) aqueous methanol with 0.2% 
formic acid was used for the electrospray solvent as this composition has been shown to 
work well for small molecules and lipids.[24] All imaging experiments were performed with 
a spot-to-spot distance of 100 μm.
Q Exactive
The IR-MALDESI imaging source was fully synchronized with a Thermo Fisher Scientific 
Q Exactive (Bremen, Germany) such that ion accumulation was triggered to overlap with 
the pulsing of the laser resulting in a single orbitrap acquisition at each pixel. The automatic 
gain control (AGC) of the instrument was turned off for all imaging experiments due to its 
incompatibility with our pulsed ionization source. The AGC is normally used to maintain a 
consistent number of ions in the orbitrap. It does so by determining the rate of ion generation 
during a prescan and varying the amount of time that ions are accumulated to reach a target 
number of ions (AGC target) for the analytical scan. With the AGC off, ions are 
accumulated for a set period of time according to the maximum ion injection time (IT). Even 
with the AGC off, mass accuracy was verified to be maintained within 1 ppm by using two 
diisooctyl phthalate peaks (391.2843 [M+H]+ and 413.266 [M+Na]+) as lock-masses in the 
instrument control software.
For broadband acquisition, two laser pulses were performed at 20 Hz (50 ms/pulse) with a 
150 ms IT to accumulate ions from both laser pulses in the C-trap followed by a single 
Orbitrap acquisition. The mass range for the orbitrap acquisition was set to 150-600 m/z. 
The mass resolution was set to 140,000 at m/z 200.
For MS2 acquisition, a targeted MS2 method file was created using an inclusion list for 
isolating the protonated ion of RAL (m/z 445.16302) with a maximum IT of 150 ms. Two IR 
pulses were performed at each pixel (20 Hz) where ions from each pulse were isolated with 
a 4 m/z window and a 1.5 m/z offset followed by ion accumulation in the C-trap. The 
accumulated ion packet was then fragmented in the HCD cell at a normalized collision 
energy of 20. All resulting fragments were analyzed in a single orbitrap acquisition. The 
normalized collision energy was optimized through the direct infusion of a RAL standard. 
Unique transitions for RAL were also determined during the direct infusion of the drug 
standards. The mass resolution was set to 140,000 at m/z 200 for the MS2 acquisition in the 
orbitrap in order to obtain high mass accuracies for the fragments.
Data Analysis
For individual ion images, the raw data (.raw) from the Thermo Q Exactive was converted to 
the mzXML format using the MSConvert software from Proteowizard[53] For the stacked 
ion images, the raw files were converted to mzML files using the MSConvert software from 
Proteowizard and were then converted to individual imzML files using imzMLConverter.
[54] The imzML Converter was then used to stack the individual imzmL files into one 
master imzML file. The mzXML or imzML files were then loaded into the standalone 
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version of MSiReader which is freely available software developed in our lab for processing 
MSI data.[55] In order to demonstrate the quality of the raw data, ion images presented in 
this manuscript were neither interpolated nor normalized (unless otherwise specified). 
MSiReader was used to extract peak intensities to the regions around the low and high 
concentration tissues in order to determine the average peak intensity for comparison with 
the absolute amounts determined by LC-MS/MS. A modified ‘hot’ colorscale was used to 
demonstrate changes in intensity. Despite its widespread use in visualizing data, the 
‘rainbow’ or ‘jet’ colorscale leads to misleading and non-intuitive distinctions between 
intensity values and was thus not used here.[56-59]
LC-MS/MS Quantitation
Tissue sections (10, 25, and 50 μm) from the low and high concentration tissue samples 
were extracted and analyzed by LC-MS/MS for TFV, FTC, and RAL concentrations. 
Sections were homogenized and extracted in 1 mL of 70:30 acetonitrile:1 mM ammonium 
phosphate (pH 7.4) using a Precellys® 24 tissue homogenizer. Calibration standards were 
prepared at 0.3, 0.6, 1.5, 6, 15, 30, 75, 150, 255, and 300 ng/mL in 70:30 acetonitrile:1 mM 
ammonium phosphate (pH 7.4). Quality control (QC) samples were prepared at 0.9, 21, and 
240 ng/mL in 70:30 acetonitrile:1 mM ammonium phosphate (pH 7.4). Following 
centrifugation, 300 μL of each standard/QC/sample was mixed with 50 μL of an internal 
standard solution (13C5-TFV, 13C15N2-FTC, and RAL-d3 at 50 ng/mL in 50:50 
methanol:water). The resulting solutions were evaporated to dryness under nitrogen at 50°C. 
Samples were reconstituted in 100 μL of 1 mM ammonium phosphate (pH 7.4) and 
transferred to a 96-well plate for LC-MS/MS analysis.
A Shimadzu HPLC system (SIL-20AC autosampler, LC-20AD pumps, and CTO-20A 
column oven; Shimadzu Scientific Instruments, Columbia, MD) was used for this analysis. 
A Waters Atlantis T3 column (2.1 mm × 100 mm, 3 μm, Waters, Milford, MA) was utilized 
at 35°C. A gradient elution using water with 0.1% formic acid (Mobile Phase A) and 
acetonitrile with 0.1% formic acid (mobile Phase B) was used to perform chromatographic 
separation. A Sciex API 5000 Triple Quad mass spectrometer (AB Sciex, Foster City, CA) 
equipped with a Turbo spray interface was used as the detector. TFV and 13C5-TFV were 
detected in negative ion mode with mass transitions of 286 → 107 and 291 →111, 
respectively. FTC, 13C15N2-FTC, RAL, and RAL-d3 were detected in positive ion mode 
with mass transitions of 248 → 130, 251 →133, 445 → 361, 448 →109, respectively.
Calibration standards and QCs for all three analytes were within 15% of nominal 
concentrations. With the tissue samples being extracted in 1 mL of solvent, the final result 
(in ng/mL) was equivalent to mass extracted (in ng) from each sample. The tissues (all < 
1mg) provided negligible volume to the homogenized sample allowing for the direct 
correlation between ng/mL and ng extracted. Since the tissue slices were too small to weigh, 
the final drug concentrations were not adjusted for tissue mass and are presented as ng 
extracted per slice.
Barry et al. Page 6























Full Acquisition IR-MALDESI MSI
Cervical tissues were incubated in either a high or low concentration of the three HIV drugs 
tenofovir (TFV), emtricitabine (FTC), and raltegravir (RAL). Two adjacent 10 μm sections 
of the high concentration tissue were thaw-mounted onto glass microscope slides. These two 
tissue sections were then imaged either with or without an ice matrix in order to validate the 
use of ice as a matrix for IR-MALDESI MSI.[37] The optical images of the tissues for both 
conditions as well as the corresponding ion maps for the protonated ions of the three 
incubated drugs are shown in Figure 1. The ion images for each drug provide clear evidence 
of the degree of improvement that can be achieved when using ice as a matrix. Also, the 
average pixel intensity and frequency of pixels in the tissue-related area where signal was 
detected (number of non-zero pixels/total number of pixels for the tissue-related area) are 
also provided for each drug under both conditions to provide a more objective comparison. 
The average pixel intensity is shown to be between about 15 fold higher for the tissue with 
ice as a matrix compared to the tissue without a matrix. While it is likely linked to the 
improvement in overall intensity, there is also marked improvement in the frequency of 
pixels with signal in the imaging experiment with ice which is especially clear for tenofovir 
which is the least abundant of the three incubated drugs. The results of these experiments 
help to validate the use of ice as a matrix for IR-MALDESI MSI and support our previous 
conclusions.[37]
The high and low concentration incubated tissues were then cryo-sectioned into several 
thicknesses (10, 25, and 50 μm) to investigate the influence of tissue thickness on the 
imaging experiment. IR-MALDESI MSI was then performed on each set of tissues (high 
and low concentration at each tissue thickness) using a broadband acquisition method where 
at each image pixel a single full mass spectrum (m/z 150-600) was collected. This broadband 
acquisition allows for the observation of all three drugs as well as any endogenous species 
that fall within the m/z range. For each tissue thickness a single imaging experiment was 
conducted which encompassed both the low and high concentration tissue sections. Ion 
images for the protonated forms of all three drugs as well as the optical images of the tissue 
sections are shown in Figure 2. All of the ion maps shown in Figure 2 are on the same 
intensity scale to demonstrate the relative intensities of all three drugs across the different 
tissue thicknesses. Coupling the IR-MALDESI imaging source with the Q Exactive has 
demonstrated a vast improvement in the analysis time necessary to complete a high 
resolving power imaging experiment. On the Q Exactive, the broadband imaging 
experiments were acquired at a rate of 1.6 scans/second. For reference, the acquisition rate 
for the same experiment on our LTQ-FT is roughly 0.5 scans/second, which represents a 
nearly threefold improvement in acquisition speed with the Q Exactive. This improvement is 
likely due to the eFT which allows for shorter transients in addition to the multiplexing 
capabilities of the Q Exactive where ions can be accumulated for the next acquisition while 
the FT analysis is being performed.
At each pixel, the laser ablates all the way through the tissue and therefore it may be 
expected that the intensity for any of the drugs from the 50 μm section should be roughly 
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five times that of the 10 μm section since there is five times more material (this assumption 
is validated from the LC-MS/MS quantification presented later). This, however, was not 
observed and the signal from all three thicknesses appears to be relatively similar. The lack 
of correlation between tissue thickness and the signal abundance could be occurring for 
several reasons. One possible explanation is that in IR-MALDESI the ablated material 
interacts with the charged solvent droplets of the electrospray plume where the analyte is 
extracted into the solvent droplets and is later ionized through an ESI-like process. The 
efficiency of this neutral capture event may inversely scale with the amount of material that 
is ablated. In essence, the extraction of analyte may be limited because there are a finite 
number of droplets present that are available for interaction with the tissue material. Despite 
this, Figure 2 shows that for a given tissue thickness there is an observable difference in 
intensity between the low and high concentrations and in fact the ratio of the average 
intensity of the low and high concentrations is consistent for all three tissue thicknesses.
Comparison of IR-MALDESI MSI with LC-MS/MS Quantitation
Tissue sections serial to those imaged by IR-MALDESI MSI were homogenized and 
analyzed by LC-MS/MS to quantify the amount of each drug that was present in both the 
high and low concentration tissues for all three tissue thicknesses. Table 2 shows the results 
of this analysis and provides the absolute amount of each drug per tissue section (ng/tissue). 
The ratio of low to high concentration was determined for each set of tissues and these 
values were then compared with the corresponding average intensity ratios from the IR-
MALDESI imaging experiments. This comparison is shown in Figure 3. It should be noted 
that differential uptake of these drugs precludes the ability to compare their incubated 
concentrations with ratios observed by LC-MS and IR-MALDESI (data not shown). Figure 
3a shows the relative intensity ratio from the low to the high concentration tissues for each 
of the three drugs. It is evident that for both techniques and the different tissue thicknesses, 
the low/high ratio clusters together for a given drug. To compare the two methods, the low/
high concentration ratios are plotted as a function of the method, thus a slope of 1 indicates 
agreement between the two methods (Figure 3b). The slope of the least-squares fit line 
through the data (forcing the intercept to 0) was around 0.74 with a correlation coefficient of 
close to 0.8. The deviation from an ideal slope of 1 is likely due to an underestimation of the 
low/high ratio by IR-MALDESI. The cause of this underestimation of the ratio is possibly 
due to the decreased frequency of detection of these drugs in the low concentration tissue 
which is a result of being near the detection limit as evidenced by Figure 2. While there 
obviously room for improvement, the low/high concentration ratios between LC-MS/MS 
and IR-MALDESI are in fairly good agreement. A correlation between MSI and LC-MS/MS 
has been demonstrated previously for other ionization methods including MALDI [18, 50, 
60-70] and DESI,[22, 71-72] but this is the first example of agreement between IR-
MALDESI MSI with LC-MS/MS. Given that LC-MS/MS is a validated quantitation 
method; the correlation between the average intensities from IR-MALDESI with the 
absolute quantities determined by LC-MS/MS provides a foundation for quantification 
directly from an imaging experiment. Direct quantitation from an MSI experiment would be 
ideal (especially for heterogeneous tissues) and is the focus of research efforts from several 
groups.[40, 61, 63-70, 72-77]
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A potential limitation of this study is the use of mucosal tissue explants incubated in drug-
containing media, rather than utilizing tissue biopsies obtained from patients receiving the 
drug. It is possible that antiretroviral uptake into explants ex-vivo differs from that observed 
in-vivo. However, the human tissue explant model has previously been validated for 
generating pharmacokinetic/pharmacodynamic (PK/PD) relationships that are clinically 
useful.[78-79] With the promising data generated from this current investigation, future drug 
distribution experiments evaluating tissues obtained from animals and humans dosed with 
these drugs are being planned.
MS2 IR-MALDESI MSI
IR-MALDESI MSI was performed as a targeted MS2 experiment for the drug RAL. Ions 
generated from two laser pulses were filtered for the protonated form of RAL using the 
selection quadrupole followed by accumulation in the C-Trap. The ions were then 
fragmented in the HCD cell and mass analyzed in the orbitrap at 140,000 RP (at m/z 200) to 
obtain accurate mass data on the fragment ions. This process was then repeated over the 
surface of the tissue such that a fragment ion ‘scan’ was acquired at each pixel in the image. 
The acquisition rate for the targeted MS2 imaging experiment was 1.5 scans/second, 
implying that very little overhead was incurred with the added step of fragmentation. Ion 
maps for the several RAL transitions are shown in Figure 4a. The colocalization of all of the 
transitions with the parent ion distribution at m/z 445 demonstrates the higher selectivity that 
can be achieved with an MRM-MSI approach. In addition, the ion abundance ratios from 
this pseudo MRM imaging experiment were compared with those obtained from the direct 
infusion ESI-MS experiment that was used to determine the optimal collision energy (Figure 
4b). As shown, the ion abundance ratios are nearly identical between the two techniques. 
This implies also that the internal energy imparted during ionization in IR-MALDESI is 
comparable to the softness of ionization in ESI as has been previously mentioned.[80]
Conclusions
We have demonstrated the capabilities of IR-MALDESI MSI coupled with the Q Exactive 
mass spectrometer. Tissue sections that were incubated with several potent and commonly 
utilized antiretroviral drugs were analyzed by IR-MALDESI MSI as well as LC-MS/MS. A 
comparison of these two methods demonstrated that the average intensities determined from 
the imaging experiments agreed well with the absolute abundances determined from a 
validated quantitation method. These experiments serve as a foundation for direct 
quantitation from tissue using IR-MALDESI MSI. In addition, a targeted MS2 imaging 
experiment was also conducted to show the added selectivity that can be attained for this 
type of analysis.
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Validation of the use of ice as a matrix for IR-MALDESI MSI. Optical images (a) of two 10 
μm serial sections of the high concentration tissue either with or without (respectively) a 
deposited layer of ice. Ion maps of (b) emtricitabine as [M+H]+, (c) tenofovir as [M+H]+, 
and (d) raltegravir as [M+H]+. In addition, the average intensity and frequency of the pixels 
with signal within the tissue area is provided for each of the ions under both conditions (with 
or without ice matrix) to demonstrate the degree of improvement that is achieved when 
using the ice matrix.
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IR-MALDESI MSI analysis of cervical tissues incubated in either a low or high 
concentration of three HIV drugs including emtricitabine (FTC), tenofovir (TFV), and 
raltegravir (RAL). Three different tissue thicknesses were investigated (10, 25, and 50 μm). 
The ion maps for all three drugs at each tissue thickness are shown on the same intensity 
scale to highlight relative differences in abundance.
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Comparison of data from LC-MS/MS and IR-MALDESI. (a) Plot of the low to high 
concentration ratios of all three drugs across the three tissue thicknesses that were 
investigated. (b) Plot of the data from both methods (LC-MS/MS vs. IR-MALDESI). A 
slope near 1 indicates relatively good agreement between the results from the LC-MS/MS 
and IR-MALDESI MSI experiments.
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Results of MRM Imaging. (a) Ion maps for the several unique transitions for raltegravir 
(RAL) that were observed from the targeted MS2 IR-MALDESI MSI experiment. The 
colocalization of all of the transitions demonstrates the increased selectivity that can be 
realized with targeted MS2 imaging techniques. (b) Comparison of the ion abundance ratios 
for selected transitions of raltegravir for both IR-MALDESI and LC-MS/MS.
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Table 1
Incubation concentrations for the three HIV drugs
Drug Abbreviation Monoisotopic Mass of [M+H]+ Low Conc. (μg/mL) High Conc. (μg/mL)
Tenofovir TFV 288.0856 3.8 100.0
Emtricitabine FTC 248.0499 18.0 100.0
Raltegravir RAL 445.1630 28.88 100.0
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Table 2
Absolute drug quantities determined by LC-MS/MS
Incubated Conc. Tissue Thickness TFV (ng/Tissue) FTC (ng/Tissue) RAL (ng/Tissue)
Low
10 0.877 3.36 2.29
25 1.91 6.95 4.90
50 4.04 14.4 10.6
High
10 8.82 9.19 12.5
25 21.9 23.1 33.2
50 43.3 44.7 64.6
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